TCM
IOVA icon

Teza Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Teza Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,317
Closed -$51K – 408
2025
Q1 		$51K Buy
+15,317
New +$79K 0.02% 398
2024
Q4 		– Sell
-12,272
Closed -$115K – 618
2024
Q3 		$115K Buy
+12,272
New +$116K 0.01% 562

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Teza Capital Management's IOVA Position: Q2 2025 in Review

Teza Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 15,317 shares — an estimated $51K sold.

Teza Capital Management first reported a position in IOVA in Q3 2024 and held it in 2 quarters. The position peaked at $115K in Q3 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Teza Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Teza Capital Management sold 15,317 Iovance Biotherapeutics shares in Q2 2025, an estimated $51K.
  • Teza Capital Management first reported a position in Iovance Biotherapeutics in Q3 2024 and held it in 2 quarters.
  • Teza Capital Management's Iovance Biotherapeutics position peaked at $115K in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.